Emmaus Life Sciences Files 8-K with Financial Results
Ticker: EMMA · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0000822370
| Field | Detail |
|---|---|
| Company | Emmaus Life Sciences, INC. (EMMA) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k, pharmaceuticals
TL;DR
Emmaus Life Sciences dropped its Q1 2026 results on 8-K, check the press release for deets.
AI Summary
Emmaus Life Sciences, Inc. filed an 8-K on March 31, 2026, reporting its financial results and condition as of March 30, 2026. The filing includes a press release dated March 30, 2026, and various financial exhibits in XBRL format.
Why It Matters
This filing provides investors with the latest financial performance and condition of Emmaus Life Sciences, Inc., crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting financial results and does not appear to contain any unusual or high-risk information.
Key Players & Entities
- Emmaus Life Sciences, Inc. (company) — Filer of the 8-K report
- March 31, 2026 (date) — Filing date of the 8-K
- March 30, 2026 (date) — Period of report for financial results
FAQ
What specific financial results are detailed in the Item 2.02 section?
The 8-K filing indicates Item 2.02 pertains to Results of Operations and Financial Condition, with a press release dated March 30, 2026, likely containing these details.
What is the significance of the XBRL documents included in the filing?
XBRL (eXtensible Business Reporting Language) documents provide structured financial data that can be more easily processed and analyzed by computers.
When was Emmaus Life Sciences, Inc. incorporated?
The filing states that Emmaus Life Sciences, Inc. is incorporated in Delaware (DE).
What is the primary business of Emmaus Life Sciences, Inc. according to the SIC code?
The SIC code 2834 indicates that Emmaus Life Sciences, Inc. is in the Pharmaceutical Preparations industry.
Where is Emmaus Life Sciences, Inc. headquartered?
The mailing and business address listed for Emmaus Life Sciences, Inc. is 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2026-03-31 08:00:39
Filing Documents
- ea0283899-8k_emmaus.htm (8-K) — 26KB
- ea028389901ex99-1.htm (EX-99.1) — 36KB
- ea028389901_ex99-1img1.jpg (GRAPHIC) — 4KB
- 0001213900-26-036886.txt ( ) — 230KB
- emma-20260330.xsd (EX-101.SCH) — 3KB
- emma-20260330_lab.xml (EX-101.LAB) — 33KB
- emma-20260330_pre.xml (EX-101.PRE) — 22KB
- ea0283899-8k_emmaus_htm.xml (XML) — 3KB
02 Results of Operation and Financial
Item 2.02 Results of Operation and Financial Condition. On March 30, 2026, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") issued a press release announcing our results of operations and financial condition as of and for the year ended December 31, 2025, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which is incorporated herein by reference. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 31, 2026 Emmaus Life Sciences, Inc. By: /s/ WILLIS LEE Name: Willis Lee Title: Chairman and Chief Executive Officer 2 INDEX TO EXHIBITS Exhibit Number Description 99.1 Press release dated March 30, 2026 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3